New contact lenses that deliver cyclosporine A for treating dry eye disease
Official title: Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response
Funded at Lynthera Corporation · NIH-10857317 · Data updated 2026-11-12
This study is testing a new type of contact lens that slowly releases a medicine called cyclosporine A to help people with dry eye feel better and get relief from irritation and burning more quickly than regular eye drops.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lynthera Corporation NIH-funded |
| Lab location | 1 site (Lancaster, United States) |
| Project start | May 1, 2021 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $795,000 |
| NIH project number | 5R44EY032424-03 |
| Project ID | NIH-10857317 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who suffer from dry eye disease.
✕Less likely to help
Patients with conditions unrelated to dry eye disease or those who are not suitable for contact lens use may not benefit from this research.
What this research studies
This research focuses on developing a drug delivery contact lens that incorporates cyclosporine A to effectively manage dry eye disease. The approach aims to enhance the delivery of this immunomodulator, which is commonly used in eye drops, by utilizing a contact lens that can provide sustained release of the medication. By improving the bioavailability of cyclosporine A through the use of hyaluronic acid, the study seeks to offer patients faster relief from symptoms such as irritation and burning. This innovative method addresses the limitations of current eye drop treatments, which often fail to provide adequate relief.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and convenient treatment option for dry eye disease.
How similar studies have gone: Other research has shown promise in using innovative drug delivery systems for ocular treatments, suggesting potential success for this approach.
Where this research is happening
-
Lynthera Corporation
Lancaster, United States Active
Researchers
- Principal investigator: Domszy, Roman — Lynthera Corporation
- Study coordinator: Domszy, Roman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.